Inovio Pharmaceuticals Inc., a biotechnology company specializing in DNA medicines for HPV-related diseases, cancer, and infectious diseases, has announced a proposed public offering of its common stock or pre-funded warrants, along with Series A and Series B warrants. This underwritten public offering is subject to market conditions and may include a 30-day option for the underwriter to purchase additional shares or warrants. Piper Sandler & Co. is serving as the sole book-running manager. The offering will proceed only through a written prospectus and prospectus supplement, which will be filed with the SEC and made available on their website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.